Clinical trial · Interventional
POSitron Emission Imaging Using 18F-FDOPA in Neurooncology
Study of the Impact of 18F-FDOPA Positon Emission Tomography on Therapeutic Proposals Made at Neurooncology Multidisciplinary Case Conferences
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
18F-FDOPA PET is expensive. It is mandatory therefore to assess its impact on the management of patients with high-grade gliomas in order to provide medico-economic justification for its use. The article by the UCLA group showed that 18F-FDOPA modified 41% of management decisions for patients with brain tumors (Walter JNM 2012). However, this study comprised 58 patients, combined primary and recurring tumors, and was based on questionnaires sent out to referring physicians. A targeted study is needed, therefore, to make a prospective multicenter assessment of the contribution of this technique in the context of high-grade glial tumors and neurooncology MCCs.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| impact of device 18F-FDOPA PET on treatment decisions | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- device 18FDOPA
- description
- impact of device 18F-FDOPA PET on treatment decisions
- interventionNames
- Other: impact of device 18F-FDOPA PET on treatment decisions
Primary outcomes (1)
- measure
- percentage of modified therapeutic decisions connected to the data supplied by 18F-FDOPA PET
- timeFrame
- up to 3 years
Secondary outcomes (1)
- measure
- Percentage of variation in the confidence level of diagnosis incorporating 18F-FDOPA PET findings (reduced, unchanged, increased).
- timeFrame
- up to 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient diagnosed with high-grade glioma * Patient whose file has been submitted to the neurooncology MCC for follow-up after initial treatment and for whom there is a diagnostic doubt * Age \> 18 years * Patient has been informed and has signed informed consent for the study Exclusion Criteria: * Patient presenting comorbidities or allergies on account of which MRI or 18F-FDOPA PET would be contraindicated.
References
Publications (1)
- RESULTDarcourt J, Chardin D, Bourg V, Gal J, Schiappa R, Blonski M, Koulibaly PM, Almairac F, Mondot L, Le Jeune F, Collombier L, Kas A, Taillandier L, Verger A. Added value of [18F]FDOPA PET to the management of high-grade glioma patients after their initial treatment: a prospective multicentre study. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2727-2735. doi: 10.1007/s00259-023-06225-0. Epub 2023 Apr 22. PMID 37086272